Cedarburg Hauser Pharmaceuticals (CHP) has expanded capacity at its Wisconsin-based API manufacturing plant and made additional upgrades aimed at improving safety and GMP systems.
 
"These improvements increase our total reactor capacity by nearly 50%," said John Flahive, CHP’s director of operations. "We have also added a reactor and chiller that allow for cryogenic reactions in our GMP labs."
 
In addition to new reactors, the company has made improvements to the air handling systems in the GMP manufacturing suites, installed a reverse osmosis water system, improved isolation capabilities, and upgraded its Emerson DeltaV Digital Automation System.